Alcon AG vs VanEck Vietnam ETF — how do they compare? Alcon AG trades at $74.32 (market cap $36.44B), while VanEck Vietnam ETF trades at $17.8. The key difference: Alcon AG pays a 0.48% dividend while VanEck Vietnam ETF pays none. Which is the better fit depends on your goals.
| ALC | VNM | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.12 | $19.80 |
52-Week Low | $62.02 | $16.34 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
VNM stock trades at $17.80, up 0.91% with a bullish technical signal despite mixed indicators. The stock faces resistance at $18 with support at $17. Recent news highlights Vietnam's economic challenges including power grid strain and FTSE Russell's EM reclassification affecting foreign investment flows.
The stock shows technical strength but faces fundamental data gaps and regional economic headwinds. Investment opportunity exists if Vietnam's market reclassification attracts foreign capital, though power infrastructure risks and broader Asian equity outflows present near-term challenges.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →